Lucid Diagnostics Reports Q4 and Full Year 2025 Results: Key Highlights for Investors
Lucid Diagnostics Reports Q4 and Full Year 2025 Results: Key Highlights for Investors
Overview
Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), released its business update and financial results for the fourth quarter and full year ended December 31, 2025. The company also held a conference call and webcast on March 26, 2026, to discuss these results and ongoing business developments.
Key Financial Highlights
- Q4 2025 Revenue: \$1.5 million recognized from EsoGuard® test sales, a notable increase compared to \$1.2 million in Q4 2024.
- Full Year 2025 Revenue: \$4.7 million, up from \$4.3 million in 2024.
- Operating Expenses: \$15.5 million for Q4 2025 (including \$1.2 million in stock-based compensation). Full year expenses were \$54.3 million, up from \$50.4 million in 2024.
- GAAP Net Loss (Q4 2025): \$16.3 million or \$(0.12) per common share, compared to \$11.5 million or \$(0.20) per share in Q4 2024.
- Non-GAAP Adjusted Loss (Q4 2025): \$12.6 million or \$(0.10) per common share, versus \$10.9 million or \$(0.19) per share in Q4 2024.
- Cash and Cash Equivalents: \$34.7 million as of December 31, 2025, an improvement from \$22.4 million the year prior.
- Shares Outstanding: 131.1 million basic and diluted shares as of Q4 2025, compared to 58.4 million in Q4 2024.
Business Development and Strategic Highlights
-
Volume Growth: Lucid processed 3,664 EsoGuard® Esophageal DNA Tests in Q4 2025, demonstrating consistent demand and physician adoption.
-
Major Contract Award: Lucid secured a significant contract with the U.S. Department of Veterans Affairs (VA), potentially expanding EsoGuard access to approximately nine million veterans across 170 VA medical centers. The contract is issued under the VA Federal Supply Schedule, with Medicare-aligned pricing of \$1,938 per test.
-
Clinical Evidence: Lucid reported positive data from the largest real-world study of esophageal precancer detection, involving nearly 12,000 at-risk patients. Results showed a 95% technical success rate for the EsoCheck® Esophageal Cell Collection Device, with 95% of procedures completed in under two minutes, and appropriate clinical use of EsoGuard by physicians.
-
Commercial and Coverage Expansion: The company is focusing on converting demand into revenue, deepening relationships with the VA, expanding adoption within health systems, pursuing commercial payor coverage, and anticipating Medicare coverage in the near term.
Detailed Financial Metrics
| Metric |
Q4 2025 |
Q4 2024 |
FY 2025 |
FY 2024 |
| Revenue (\$ thousands) |
1,504 |
1,197 |
4,706 |
4,346 |
| Operating Expenses (\$ thousands) |
15,514 |
13,571 |
54,346 |
50,398 |
| Other (Income) Expense (\$ thousands) |
2,256 |
(833) |
8,370 |
(523) |
| Net Loss (\$ thousands) |
(16,266) |
(11,541) |
(58,010) |
(45,529) |
| Net Loss per Common Share |
(0.12) |
(0.20) |
(0.69) |
(1.05) |
| Non-GAAP Adjusted Loss (\$ thousands) |
(12,636) |
(10,882) |
(44,043) |
(40,005) |
| Non-GAAP Adjusted Loss per Share |
(0.10) |
(0.19) |
(0.43) |
(0.79) |
Non-GAAP Measures and Adjustments
The company provides non-GAAP financial measures such as EBITDA and non-GAAP adjusted loss to supplement its audited financial results. These measures adjust for non-cash and financing-related expenses, aiming to provide a clearer view of operational performance for investors and management.
- Stock-based compensation for 2025 was \$4.5 million.
- Other non-cash adjustments included changes in fair value of convertible debt, loss on debt extinguishment, and equity issuance costs.
- Net operating expenses (excluding certain non-cash adjustments) for 2025 totaled \$48.7 million, up from \$44.4 million in 2024.
Outlook and Potential Share Price Drivers
-
VA Contract: Expansion into the VA network is a major milestone, unlocking access to a large patient base and offering revenue visibility with Medicare-aligned pricing. This contract has the potential to significantly accelerate test adoption and revenue growth.
-
Clinical Validation: Positive real-world clinical data supports broader adoption of Lucid’s products, which may drive increased market penetration and payer coverage.
-
Financial Position: Lucid’s improved cash position (\$34.7 million) provides operational runway for continued commercialization and growth initiatives.
-
Coverage Expansion: Progress toward Medicare and commercial payor coverage could be a significant catalyst for future revenue and share price appreciation.
-
Risks: Despite increased revenue and operational progress, Lucid continues to report substantial operating losses and faces uncertainties regarding regulatory, payer, and market adoption. Shareholder dilution (as seen in the increased share count) may also be a concern.
Company Profile
Lucid Diagnostics is focused on early detection and prevention of esophageal cancer among millions of GERD patients at risk. Its flagship products, EsoGuard® and EsoCheck®, enable noninvasive, office-based testing for esophageal precancer, targeting improved outcomes and reduced mortality through early intervention.
Forward-Looking Statements
This article contains forward-looking statements based on current expectations, which involve risks and uncertainties. Actual results may differ materially due to various factors, including market conditions, regulatory hurdles, payer coverage, operational challenges, and financial needs. Investors should review the company’s public filings for a comprehensive discussion of risks.
Disclaimer
The information presented herein is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with financial professionals before making investment decisions. The author and publisher accept no liability for actions taken based on this content.
View Lucid Diagnostics Inc. Historical chart here
